Navigation Links
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Date:1/22/2009

SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today results of a study published by Esmaeli, et al. online on January 15, 2009 in the Annals of Oncology demonstrating that rituximab followed by single agent Zevalin (ibritumomab tiuxetan) in a front-line setting for patients with MALT lymphoma and low- grade follicular lymphoma that primarily involved the conjunctiva or orbit produced a complete response rate of 83 percent.

Ocular adnexal lymphoma (OAL) defined as lymphoma affecting the orbit, eyelid and conjunctiva is the most frequent primary malignant tumor of the orbit in adults, accounting for approximately 55 percent of all orbital tumors. MALT lymphoma is the most common histologic subtype of OAL, followed by low-grade follicular lymphoma. External-beam radiotherapy (EBRT) has been the most frequently used modality and is considered the gold standard for treating OAL that present with local disease. However, EBRT does not address systemic sites of involvement in OAL in patients with multifocal disease and therefore, systemic targeted radioimmunotherapy with Zevalin might offer an alternative to treating OAL.

"This study demonstrates the potential for Zevalin to provide an alternative to EBRT, the current standard of therapy for MALT lymphoma, which may result in lower ocular toxicity than EBRT and equivalent or better disease control," noted Jack Singer, M.D. and Chief Medical Officer of CTI.

In the study 9 patients with MALT lymphoma of conjunctiva or orbit and 3 patients with low grade follicular lymphoma of the orbit received rituximab and Indium-111 Zevalin and then approximately 1 week later received a second infusion of rituximab followed by single dose of Yttrium-90 Zevalin.

Results demonstrated an initial response rate for patients of 100 percent with 83 percent achieving a complete response. There were
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... to about 300,000 Children and Families, , ... ... One month after Haiti experienced the worst natural disaster in ... and adults in the earthquake impact zone. , , , ... humanitarian agency has been providing emergency assistance to save lives, ...
(Date:2/9/2010)... lost much more weight than peers who tried lifestyle ... obese teens who received gastric banding surgery lost significantly ... as dieting and exercise, Australian researchers report. , Their ... a body-mass index (BMI) higher than 35 (statistical obesity ... adjustable gastric banding while the other half took part ...
(Date:2/9/2010)... found larger, for-profit hospitals more likely to insert them ... and those that are set up to make a ... patients with advanced dementia, despite evidence that the practice ... and other problems. , "Our results suggest that decisions ... go to than a decision-making process that really elicits ...
(Date:2/9/2010)... SAINT PAUL, Minn. , Feb. 9 ... death, chronic obstructive pulmonary disease (COPD), is now ... Environmental Public Health Tracking Program. The program focuses ... Minnesota that can be triggered or made ... or outdoor air pollution — asthma, heart attacks ...
(Date:2/9/2010)... a Gift for ... ,, CHICAGO , Feb. 9 /PRNewswire-USNewswire/ ... by giving a gift for the heart ... Fast, and Flavorful Recipes Made with Canola Oil" by ... cook some of these recipes for love or give ...
Breaking Medicine News(10 mins):Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 3Health News:Gastric Banding Most Effective for Obese Teens 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3
... Visions, Inc., a premier,event production and audio-visual integration ... was acquired by Interactive Holdings, a leading,communication solutions ... Creative Visions is best known for producing world ... Palace of Versailles, Sydney Opera House,Blenheim Palace and ...
... Paramedics and emergency medical technicians (EMTs) employed by ... members of Teamsters Local 375 attended the company,s annual ... Employee shareholders expressed their frustration with the company,s reluctance ... new contract in the greater Buffalo, New York area, ...
... Newsletter Series for Physicians , , ... difficile infection (CDI) in geriatric and ... observed increase in CDI incidence in many age groups, healthcare ... of these patient populations. , , ...
... corporate leaders joined together today to unveil the new Houston ... a model for other cities also struggling with the crisis ... The clinic is a joint project between janitors and responsible ... Baylor College of Medicine -- to make health care ...
... /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: CHDX ... healthcare,products and services in the People,s Republic of ... offered not to accept any increases in,their respective ... for fiscal 2009. This unsolicited offer has ...
... at same dosage used to improve cognitive impairment, ... -- Drugs used to treat Alzheimer,s patients, cognitive ... for behavioral and psychological symptoms such as aggression, ... , They reviewed nine studies that examined the ...
Other Medicine News:Health News:Creative Visions Acquired by Interactive Holdings 2Health News:Creative Visions Acquired by Interactive Holdings 3Health News:Current Concepts in Clostridium difficile Infection: A Focus on Geriatric and Pediatric Patients 2Health News:SEIU Janitors and Responsible Corporate Leaders Herald New Model for Making Health Care More Accessible and More Affordable 2Health News:Chindex International, Inc. Adopts Voluntary Executive Compensation Restrictions 2Health News:Chindex International, Inc. Adopts Voluntary Executive Compensation Restrictions 3Health News:Alzheimer's Drugs Also Treat Behavioral, Psych Problems 2
(Date:2/9/2010)... February 9 Debiopharm ... companies with,a focus on the development of ... announced the signature of an exclusive licence ... commercialisation of Debio 025,(alisporivir), a selective, first-in-class ... virus (HCV) effect. The product is currently ...
(Date:2/8/2010)... , Feb. 8 Cost reductions ... Products (Nasdaq: AHPI ) narrowly back into profitability ... Sales for the quarter ended December 31, 2009 ... million during the same quarter last year to ... Allied,s costs of sales were reduced even more sharply, ...
(Date:2/8/2010)... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... for the fourth quarter and year-end 2009 following the ... 2010 . ,, Paul Hamelin , President ... Officer, will host an investment community conference call beginning ... February 26, 2010 to discuss these results and ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Impact Factor names Cell top research journal 8967 1Rotary Marks Progress in Drive to Eradicate Polio 49766 1Rotary Marks Progress in Drive to Eradicate Polio 49766 2Rotary Marks Progress in Drive to Eradicate Polio 49766 3ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 1ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 2
... Therapeutics Limited,one of the UK,s leading pre-IPO biotechnology ... study with its oral, once-daily experimental,cancer therapy CHR-2797 ... (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM),who ... chemotherapy., Headline data from the study, which ...
... CARLOS, Calif., Dec. 12 Nuvelo, Inc.,(Nasdaq: ... patient in a Phase 2,proof-of-concept trial of alfimeprase ... has also been granted fast track designation by ... in this indication. Fast,track designation, which was mandated ...
Other Medicine Technology:Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 3Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 4
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
... Off-white free flowing powder. pH: pH(4.7%, ... Casein Peptone: 24% Yeast Extract: 47% Potassium Phosphate ... To Use: Dissolve 47 gm powder per liter ... of plasmid DNA and recombinant proteins than LB ...
...
Medicine Products: